Our Vision: To understand and harness the therapeutic potential of the cannabis plant and thereby improve the quality of life for patients around the world.

European Growth

Over the last four years, Avextra has built one of the only vertically integrated EU operations from genetic selection and cultivation to sales and distribution. By effectively and responsibly deploying capital, we’ve built valuable assets strategically across Europe and are already present in some of the biggest EU markets.

Assets strategically developed across Europe

Country access
via high calibre partners

Avextra license/



Avextra controls the entire value chain

From genetic selection through to product innovation

Genetic Selection and Cultivation

Product Development and R&D

Production and Manufacturing


Clinical Pipeline


We have a 600m2 purpose-built cultivation facility on 250ha of land in Portugal to cultivate rare genetics for indication-based formulations.

Check out our state- of-the-art medical cannabis cultivation facility in Portugal in this behind-the-scenes.


Focused development of novel extract-based product innovations


In a 10,000m2 state-of-the-art GMP manufacturing facility in Germany and a highly qualified team with 75 years of experience in botanical extraction of plant-based medicines.


Our products are already present in 4 of the biggest EU markets with expansion plans in place. We have one of the largest sales team in Germany, equipped with exceptional connections.

Here you see some placeholder text to explain the picture.


Clinical Program in place to gather product-specific data for future commercials, with 3 clinical programs starting in 2023.

Keep We invest a third of our total budget in Research & Development

Press Releases

Avextra AG Announces Closing of EU 17 Million Capital Raise

Avextra AG Announces Closing of EU 17 Million Capital Raise

Avextra announces the closing of its EU 17 Million Convertible Loan Note (“CLN”) bridge capital raise. The CLN will automatically swap into equity at the next capital round currently in…

Avextra Successfully Exports Oil-Based Cannabis Medicines to the United Kingdom

Avextra Successfully Exports Oil-Based Cannabis Medicines to the United Kingdom

BENSHEIM, Germany, Feb. 08, 2023 (GLOBE NEWSWIRE) — Avextra AG (“Avextra” or the “Company”), a leading vertically-integrated manufacturer of Cannabis-based medicines located in Germany, is pleased to announce the successful…

Medical Device Submission für ein Inhalationsdevice

Medical Device Submission für ein Inhalationsdevice

Avextra has commissioned the Leading Medical Device Specialists Activoris and Actarmo to prepare the EU Medical Device Submission for a Cannabis Extract Inhaler Together these three partners will develop a…

Eurox has rebranded as Avextra

Eurox has rebranded as Avextra

Bensheim, 14.9.2022 – Eurox has rebranded as Avextra. The leading manufacturer of cannabis-based medicines Made in Germany will premiere under its new name at the Expopharm Pharmacists’ Congress in Munich…


We are always looking to connect with those who share our vision. If you’re interested in receiving a detailed deck and discovering how you can be part of our success, please contact us today.